Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Spectral AI (MDAIW) Gains from Sales and Divestitures (2023 - 2025)

Spectral AI posted quarterly Gains from Sales and Divestitures of $159700.0 for Q4 2025, up 23.71% year-on-year from $129097.0 in Q4 2024, and up 45.58% on a QoQ basis from $109700.0 in Q3 2025.

Spectral AI (MDAIW) has 3 years of Gains from Sales and Divestitures data on file, last reported at $159700.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 23.71% year-over-year to $159700.0; the trailing twelve-month figure through Dec 2025 stood at $159700.0 (up 23.71% YoY), and the FY2025 full-year result was $159700.0, up 23.71% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $159700.0, up from $109700.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $159700.0 in Q4 2025 and bottomed at $29097.0 in Q3 2024.
  • The 3-year median for Gains from Sales and Divestitures is $70009.0 (2023), against an average of $78378.5.
  • Peak annual rise in Gains from Sales and Divestitures reached 325.81% in 2024, while the deepest fall reached 4.03% in 2024.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $30318.0 in 2023, then soared by 325.81% to $129097.0 in 2024, then grew by 23.71% to $159700.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $159700.0 (Q4 2025), $109700.0 (Q3 2025), and $109700.0 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Spectral AI - - 2.03 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 159,700.00
Dec 31, 2025 159,700.00
Sep 30, 2025 109,700.00
Sep 30, 2025 109,700.00
Jun 30, 2025 109,700.00
Jun 30, 2025 109,700.00
Dec 31, 2024 129,097.00
Dec 31, 2024 129,097.00
Sep 30, 2024 29,097.00
Sep 30, 2024 29,097.00
Jun 30, 2024 29,098.00
Jun 30, 2024 29,098.00
Dec 31, 2023 30,318.00
Dec 31, 2023 30,318.00
Sep 30, 2023 30,318.00
Sep 30, 2023 30,318.00